Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes ...

Tissue inadequacy and operational challenges may limit lung cancer comprehensive biomarker testing. Here, we describe the initial implementation of a tailored tissue molecular journey at Oncoclínicas ...

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor Plus as well as its Liquid Trace Hematology ...

Genomic Testing Cooperative Receives UKCA Mark for its Portfolio of Hematology, Solid Tumors and Liquid Biopsy Profiles covering DNA and RNA Genomic Testing Cooperative (GTC) today announced it ...